Inactive Instrument

China Biologic Products Holdings, Inc.

Equities

CBPO

KYG215151047

Biotechnology & Medical Research

China Biologic Products Holdings, Inc. Provides Earnings Guidance for 2019

May 13, 2019 at 07:30 am EDT

China Biologic Products Holdings, Inc. provided earnings guidance for 2019. For the period, the company's operating profit remaining at bottom line growth of 4% to 6% in RMB terms on a year-over-year basis.

Latest news about China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from S&P Global BMI Index	21-04-23	CI
China Biologic Products Holdings, Inc.(NasdaqGM:CBPO) dropped from FTSE All-World Index	21-04-23	CI
China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from NASDAQ Biotechnology Index	21-04-20	CI
China Biologic Products Holdings, Inc.(NasdaqGM:) dropped from NASDAQ Composite Index	21-04-20	CI
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow, Chairman and Chief Executive Officer of China Biologic Products Holdings, Inc. completed the acquisition of remaining 31.16% stake in China Biologic Products Holdings, Inc..	21-04-19	CI
China Biologic Products Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
China Biologic Products : Q4 Profit, Revenue Rise from Year Ago	21-03-29	MT
China Biologic Products Holdings, Inc. Announces Resignation of Yue’e Zhang from the Board of Directors	21-01-07	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 9.72% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	21-01-05	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	21-01-04	CI
CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	20-12-29	CI
Transcript : China Biologic Products Holdings, Inc., Q3 2020 Earnings Call, Nov 25, 2020	20-11-25
China Biologic Products Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-24	CI
China Biologic Products : Q3 Adj. EPS Slips From Year-Ago Levels But Sales Climb Nearly 2%	20-11-24	MT
China Biologic Products : to Merge With CBPO Group in Going-Private Deal; Shares Gain Pre-Bell	20-11-19	MT
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow entered into a definitive Agreement and Plan of Merger to acquire remaining 31.16% stake in China Biologic Products Holdings, Inc. for $1.6 billion.	20-11-18	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 9.72% stake in China Biologic Products Holdings, Inc. for approximately $450 million.	20-10-26	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for $93 million.	20-10-26	CI
CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for approximately $110 million.	20-10-26	CI
Transcript : China Biologic Products Holdings, Inc., Q2 2020 Earnings Call, Aug 18, 2020	20-08-18
China Biologic Products Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-17	CI
Transcript : China Biologic Products Holdings, Inc., Q1 2020 Earnings Call, May 21, 2020	20-05-21
China Biologic Products Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-20	CI
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction	20-05-20	CI
Hillhouse Capital Provides Information to Shareholders of China Biologic	20-05-08	CI

Chart China Biologic Products Holdings, Inc.

Duration

Period

Chart China Biologic Products Holdings, Inc.

More charts

Company Profile

China Biologic Products Holdings Inc is a China-based company. The Company operates as a biopharmaceutical company. The Company research, develop, and produces human plasma-based pharmaceutical and coagulation factor products in the form of tablets, injections, capsules, and syrups. Company also distributes pharmaceutical products. It serves clients in China.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs